Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients. [electronic resource]
Producer: 20160520Description: 893-8 p. digitalISSN:- 1545-9616
- Adalimumab -- therapeutic use
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Dermatologic Agents -- therapeutic use
- Etanercept -- therapeutic use
- Female
- Humans
- Infliximab -- therapeutic use
- Male
- Middle Aged
- Psoriasis -- drug therapy
- Retreatment
- Retrospective Studies
- Severity of Illness Index
- Treatment Failure
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Ustekinumab -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.